By Natalie Howard, DNP, FNP-C — The Health Think Tank
Can GLP-1 medications like Ozempic, Wegovy, and Zepbound lower your breast cancer risk? The honest answer: maybe, but it is not proven. Several 2025–2026 studies found that women taking GLP-1 medications were diagnosed with breast cancer less often — but these are observational studies that cannot show the drug is the cause, and one key comparison (GLP-1 versus SGLT2 inhibitors) erased the benefit entirely. What the data really points to is the underlying metabolic environment — insulin, inflammation, and post-menopausal estrogen — a risk factor you can influence with or without medication.
A clinician’s read of the three new GLP-1 and breast cancer studies. The full written breakdown continues below.
What did the new GLP-1 and breast cancer studies find?
Three separate analyses, published between August 2025 and June 2026, pointed in the same direction.
The Penn Medicine study (McDonald et al., JCO Oncology Practice, 2026; DOI 10.1200/OP-26-00485; ASCO 2026 Abstract 10506) reviewed records from 111,646 women ages 45 to 80 with a BMI of 25 or higher. Women on GLP-1 medications had an odds ratio of 0.695 (95% CI 0.590–0.819) for a breast cancer diagnosis — about 30% lower odds. But in absolute terms the gap was small: 1.62% of GLP-1 users were diagnosed versus 2.31% of non-users, an absolute risk reduction of roughly 0.69 percentage points. The authors describe the result as hypothesis-generating, not proof of cause.
The JAMA Oncology study (Dai et al., 2025; DOI 10.1001/jamaoncol.2025.2681) followed 86,632 adults eligible for weight-loss medication and found overall cancer risk about 17% lower (HR 0.83, 95% CI 0.76–0.91). Breast cancer specifically was only about 14% lower and did not reach statistical significance on its own — the individually significant reductions were in endometrial, ovarian, and meningioma cancers.
The JAMA Network Open study (Tatum et al., 2026; DOI 10.1001/jamanetworkopen.2026.12133) asked a different question: outcomes in women who already had breast cancer. Among those with obesity, GLP-1 use was linked to a 65% lower 10-year mortality risk (HR 0.35, 95% CI 0.21–0.58) and lower recurrence-or-death (HR 0.44).
Do these studies prove GLP-1 prevents breast cancer?
No. All three are observational, and there are three specific reasons to be cautious.
The SGLT2 comparison. In the survival study, the benefit looked dramatic when GLP-1 users were compared against older diabetes drugs or no medication. But when compared head-to-head against another modern drug class — SGLT2 inhibitors — the difference disappeared (HR 0.97, not significant). That strongly suggests a large part of the “benefit” reflects which patients get and stay on modern medication, not a unique anticancer property of GLP-1.
The matched numbers are small. The survival study’s 841,831-patient database shrank to about 1,610 patients in the matched obesity arm after balancing. One arm reported a 91% mortality reduction — implausibly large for a drug effect, and a classic signature of selection bias.
The researchers say so themselves. Penn’s lead author stated plainly that the study is observational and does not confirm an association, which is why the team is launching a randomized controlled trial.
Why might GLP-1 be linked to lower breast cancer risk at all?
The likely common thread isn’t the drug brand — it’s the metabolic environment. Excess body fat behaves as an active endocrine organ: it raises circulating insulin, drives chronic low-grade inflammation, and, after menopause, becomes a primary site of estrogen production. Higher insulin, more inflammation, and greater estrogen exposure are each independently associated with breast cancer risk and worse outcomes.
GLP-1 medications move that environment for some people by reducing fat mass. But so do other levers — losing visceral fat, building muscle, resistance training, and sleep — independent of medication.
What should you actually do?
- If you take a GLP-1: treat this as cautious optimism, not a cancer shield. Keep all breast cancer screening on schedule.
- If you don’t: read these studies as a spotlight on metabolic health you can start changing now, not as a prescription.
- Either way: ask your provider about your metabolic risk profile and the full set of levers available to you, not just the drug.
Frequently asked questions
No. Observational studies link GLP-1 medications like Ozempic to fewer breast cancer diagnoses, but they do not prove cause. A randomized trial is underway to test whether the effect is real.
The largest study (Penn, 2026) found about 30% lower odds of diagnosis (OR 0.695) in a matched cohort of overweight and obese women — though the absolute risk reduction was under 1 percentage point. A separate JAMA Oncology study found breast cancer about 14% lower, but that result was not statistically significant on its own.
A 2026 study suggested better survival outcomes among breast cancer patients with obesity who used GLP-1s, but the evidence is observational and not conclusive. Survivors should discuss GLP-1 use individually with their oncology team.
Excess body fat raises insulin, increases chronic inflammation, and increases post-menopausal estrogen production — all independently associated with breast cancer risk and outcomes.
This article is clinical education, not medical advice, and does not create a provider–patient relationship. Talk to your own clinician about your care.
The companion video uses an AI-generated presenter and visuals. The clinical analysis is the work of Dr. Natalie Howard, DNP, FNP-C.
References
- McDonald ES, et al. JCO Oncol Pract. 2026. doi:10.1200/OP-26-00485.
- Dai H, et al. JAMA Oncol. 2025. doi:10.1001/jamaoncol.2025.2681.
- Tatum KL, et al. JAMA Netw Open. 2026;9(5):e2612133. doi:10.1001/jamanetworkopen.2026.12133.